National Institutes of Health (NIH) is halting its clinical trial of hydroxychloroquine, saying the malaria drug provides no benefits to those with COVID-19.In a press release issued Saturday morning, the NIH said the agency’s data and safety monitoring board (DSMB) met on Friday and determined that while there was no harm, hydroxychloroquine was “very unlikely to be beneficial to hospitalized patients with COVID-19.”“After its fourth interim analysis the DSMB, which regularly monitors the trial, recommended to the National Heart, Lung, and Blood Institute (NHLBI), part of NIH, to stop the study.